Morcellator Lawsuit Investigation: Bernstein Liebhard LLP Notes Decision by Florida Hospitals to Suspend Uterine Morcellation in Light of Cancer Risk - Hawaii News Now - KGMB and KHNL

Morcellator Lawsuit Investigation: Bernstein Liebhard LLP Notes Decision by Florida Hospitals to Suspend Uterine Morcellation in Light of Cancer Risk

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact

SOURCE Bernstein Liebhard LLP

NEW YORK, June 11, 2014 /PRNewswire/ -- As the Firm continues its investigation of morcellator lawsuits (, Bernstein Liebhard LLP notes that several Florida hospitals have decided to suspend uterine morcellation procedures in light of their potential to spread uterine cancers. According to a report posted on on June 7th, those hospital include Tampa General Hospital, BayCare Health System, the Florida Hospital System, Bayfront Health St. Petersburg and local hospitals owned by Community Health Systems.  HCA (Hospital Corporation of America) has also asked facilities in the state to comply with an alert issued by the U.S. Food & Drug Administration (FDA) in April that discouraged the use of power morcellation in laparoscopic hysterectomy and fibroid removals, due to the risk that the device can spread undiagnosed uterine sarcoma and other cancers outside of the uterus.

Bernstein Liebhard LLP

"These Florida hospitals join The Cleveland Clinic, Brigham and Women's in Massachusetts, and many others around the country that have chosen to suspend or limit the use of uterine morcellation due to the FDA's April alert," says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is now offering free morcellator lawsuit reviews to women who may have experienced the spread of undiagnosed uterine sarcoma and other cancers due to uterine morcellation.

Morcellator Cancer Risks

Power morcellators are used during laparoscopic hysterectomies and fibroid removals to shred tissue in order to facilitate its removal through a small abdominal incision. According to the alert issued by the FDA on April 17th, about 1 in 350 women with fibroids has undiagnosed uterine sarcoma cells in that tissue. Because pre-screening for such cancer is unreliable, the FDA discouraged doctors from using power morcellators in minimally-invasive gynecological surgeries. If such cancers are spread outside of the uterus, the chance of a patient's long-term survival is greatly diminished.

Last month, the FDA warning prompted Johnson & Johnson to announce that it would suspend sales of three Ethicon, Inc. devices, the Gynecare Morcellex, Morcellex Sigma Tissue Morcellator System, and Gynecare X-Tract Tissue Morcellator products.

The FDA will convene a meeting of its Obstetrics and Gynecological Devices Panel beginning on July 10th to further review the cancer risks associated with power morcellators. During the two-day proceeding, the Panel will be tasked with making recommendations regarding the appropriate use, premarket testing, labeling, and other risk mitigation for power morcellators used in laparoscopic hysterectomy and fibroid removal procedures.

Women who may have experienced the spread of uterine sarcomas or other cancers following uterine morcellation may be eligible to file a morcellator cancer lawsuit against the company that manufactured the device used in their surgery. To learn more about filing a morcellator lawsuit, please visit Bernstein Liebhard LLP's website. Free case reviews can also be obtained by calling (888) 340-4807.

About Bernstein Liebhard LLP 

Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs' Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP represents the victims of defective drugs and medical devices on a contingency-fee basis, and our clients are never expected to pay attorney fees unless their case results in a successful recovery on their behalf. New York State's contingency fee cap rules generally limit those fees to 33 1/3% of the total recovery. As a result, the Firm's fees can be significantly lower than those assessed by attorneys in other states, which depending on the law may amount to as much as 40% or more of a plaintiff's recovery.

Bernstein Liebhard LLP 
10 East 40th Street 
New York, New York 10016 
(888) 340-4807

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (888) 340-4807. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information: 
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com

Logo -

©2012 PR Newswire. All Rights Reserved.